BACKGROUND The management of neovascular age-related macular degeneration (nAMD) has been transformed by the introduction of agents delivered by intravitreal injection which block the action of vascular endothelial growth factor-A (anti-VEGF agents). One such agent in widespread use is bevacizumab which was initially developed for use in oncology. Most of the evidence supporting the use of beva...

purpose: to compare repeated intravitreal injections of bevacizumab (ivb) with triamcinolone acetonide (ivt) for treatment of acute branch retinal vein occlusion (brvo). methods: this randomized clinical trial included, 86 eyes with recent onset (less than 12 weeks) brvo. participants were randomly assigned to two treatment groups: the ivb group (43 eyes) consisted of patients who received mont...

PURPOSE To determine the incidence of rebound macular edema after intravitreal bevacizumab in eyes with macular edema secondary to branch retinal vein occlusion and to identify the pretreatment factors that were significantly associated with the rebound. METHODS The changes in the foveal thickness after the intravitreal bevacizumab (1.25 mg/0.05 mL) were studied in 65 eyes of 65 patients with...

Introduction: Intravitreal Avastin (bevacizumab) injection is reportedly accompanied by ocular and systemic side-effects. Our enquiry assesses whether there are any differences between intraocular pressure (IOP) in baseline and on the day after injection in patients treated for retinal disease. Methods: In this experimental study, 82 eyes with retinal diseases that had indication for anti-VEGF...

OBJECTIVE To examine the efficacy of intravitreal bevacizumab for pain relief in eyes with refractory neovascular glaucoma. METHODS In this prospective case series, 52 eyes with neovascular glaucoma were administered intravitreal bevacizumab, 1.25 mg, and monitored for 6 months. The primary outcome measure was change in subjective pain score. Intraocular pressure and iris neovascularization w...

BACKGROUND/AIM To evaluate refractive and strabismic results and the efficacy of intravitreal bevacizumab in retinopathy of prematurity (ROP) ineligible for laser therapy. MATERIALS AND METHODS Thirty-nine eyes of 20 consecutive infants with high-risk prethreshold ROP (11 infants with Zone I and 9 infants with Zone II disease) who were ineligible for laser therapy due to systemic and/or ocula...

PURPOSE To evaluate subfoveal choroidal thickness in patients with central retinal vein occlusion (CRVO) using enhanced depth imaging optical coherence tomography. DESIGN Retrospective observational study. METHODS We measured bilateral subfoveal choroidal thickness, averaged for 100 scans, in 36 patients (mean age, 66 ± 15 years; 26 women and 10 men) with unilateral CRVO by using the enhanc...

AIM To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab. METHODS A 55-year-old man had diabetes with unilateral rubeosis and macular edema. Three days after receiving intravitreal injection of bevacizumab (1.25 mg in 0.1 ml), he developed acute vision loss and change of consciousness. A complete ocul...

PURPOSE OF REVIEW New treatment modalities for branch retinal vein occlusion have recently been introduced. The role of intravitreal bevacizumab injections will be discussed and compared with laser photocoagulation and other novel intravitreal pharmacotherapies. RECENT FINDINGS Argon laser photocoagulation is the single treatment for branch retinal vein occlusion that has been shown to reduce...

PURPOSE To report on the therapeutic effect of intravitreal low-dose bevacizumab for treatment for retinopathy of prematurity (ROP). METHODS The single-centre retrospective, non-comparative case series study included all infants who consecutively underwent intravitreal injection of 0.375 mg bevacizumab (0.03 ml) under light sedation in topical anaesthesia as therapy of ROP in zone I or zone I...